3 unknown. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Unknown 3 |
Follow Toxemia: new trials by email Literature Review of Toxemia trials Research Report on Toxemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia Dexamethasone, Tocilizumab, Anakinra - Sepsis, Neuroinflammatory Response | Phase 4 | Unknown | Radboud University Medical Center | 52 | 2024-10-24 | 2025-04-04 |
| A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Vitamin D3 - Gestational Hypertension, Toxemia | Phase 4 | Unknown | Stony Brook University | 412 | 2016-10-01 | 2017-10-05 |
| Rifaximin Predicts the Complications of Decompensated Cirrhosis rifaximin - Cirrhosis | Phase 4 | Unknown | Shanghai Changzheng Hospital | 250 | 2013-10-01 | 2014-02-28 |
Endotoxemia (2) · Eclampsia (1) · Fibrosis (1) · HELLP Syndrome (1) · Hypertension, Pregnancy-Induced (1) · Neuroinflammatory Diseases (1) · Sepsis (1)
Infections (3) · Bacteremia (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Systemic Inflammatory Response Syndrome (2) · Cardiovascular Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hypertension (1) · Nervous System Diseases (1) · Pregnancy Complications (1) · Sepsis (1) · Urogenital Diseases (1) · Vascular Diseases (1)
Cholecalciferol (1) · Dexamethasone (1) · Endotoxins (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lipopolysaccharides (1) · Rifaximin (1) · Sodium Chloride (1) · Vitamin D (1) · tocilizumab (1)
Radboud University Medical Center (1) · Shanghai Changzheng Hospital (1) · Stony Brook University (1)
China (1) · Netherlands (1) · United States (1)
Diana J Garretto, MD (1) · Wei-Fen Xie, MD (1)
2023 (1)